{"id":"actilitio","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Hypothyroidism"},{"rate":"1-5%","effect":"Hyperthyroidism"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"<1%","effect":"Colitis"},{"rate":"<1%","effect":"Pneumonia"},{"rate":"<1%","effect":"Nephritis"},{"rate":"<1%","effect":"Arthralgia"},{"rate":"<1%","effect":"Myalgia"},{"rate":"<1%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, Actilitio prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.","oneSentence":"Actilitio is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:38.943Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Urothelial carcinoma"},{"name":"Renal cell carcinoma"},{"name":"Gastric cancer"},{"name":"Esophageal cancer"},{"name":"Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer"},{"name":"Cervical cancer"},{"name":"Hepatocellular carcinoma"},{"name":"Mucosal melanoma"}]},"trialDetails":[{"nctId":"NCT06861842","phase":"PHASE4","title":"Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centro de Atencion e Investigacion Medica","startDate":"2024-06-01","conditions":"Healthy, Healthy Donors","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lithium carbonate"],"phase":"marketed","status":"active","brandName":"Actilitio®","genericName":"Actilitio®","companyName":"Centro de Atencion e Investigacion Medica","companyId":"centro-de-atencion-e-investigacion-medica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Actilitio is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Urothelial carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}